Apriori Bio develops Octavia™, a biology-informed AI platform that characterizes large libraries of viral variants for cell binding and immune evasion, then uses machine learning to map mutations with high escape potential. The platform combines computational insights and experimental biological data, including analysis of evolutionary trees and interactions between mutations, to predict where viral variability is most likely to occur. Insights from Octavia are intended to guide vaccine design and updates and to inform public-health policy in real time. The company was founded in 2020 by Flagship Pioneering and is led by CEO Lovisa Afzelius. Apriori is based in Boston, MA. The article reports a recent funding event in which the company received financial support to continue advancing Octavia and to expand focus beyond coronavirus. Apriori Bio, founded in 2020 and based in Cambridge, MA, develops tools to protect humanity from rapidly evolving viruses. Its core product, Octavia, is a biology-informed AI platform that can infer the full landscape of potential variants for a given virus. Using Octavia, Apriori defines the antibody repertoire that most broadly protects against current and future variants, enabling development of variant-proof vaccines and antibody drugs. The platform can also inform public health policy in real time by predicting the impact of emerging variants. Flagship Pioneering announced an initial $50 million commitment at launch to fund Apriori's work. Apriori aims to design vaccines and antibody therapeutics that anticipate viral evolution to provide long-term, variant-resistant protection.

Total raised

$51M

Funding rounds

2

Latest round

Seed

Latest activity

Jul 2024